GSK PLC-SPON ADR (GSK) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:GSK • US37733W2044

60.23 USD
+1.06 (+1.79%)
At close: Feb 6, 2026
60.03 USD
-0.2 (-0.33%)
After Hours: 2/6/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to GSK. GSK was compared to 191 industry peers in the Pharmaceuticals industry. While GSK belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on GSK.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year GSK was profitable.
  • In the past year GSK had a positive cash flow from operations.
  • In the past 5 years GSK has always been profitable.
  • Each year in the past 5 years GSK had a positive operating cash flow.
GSK Yearly Net Income VS EBIT VS OCF VS FCFGSK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • GSK's Return On Assets of 9.35% is amongst the best of the industry. GSK outperforms 91.10% of its industry peers.
  • With an excellent Return On Equity value of 34.90%, GSK belongs to the best of the industry, outperforming 95.29% of the companies in the same industry.
  • GSK's Return On Invested Capital of 19.19% is amongst the best of the industry. GSK outperforms 95.81% of its industry peers.
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROIC 19.19%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GSK Yearly ROA, ROE, ROICGSK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • With an excellent Profit Margin value of 17.50%, GSK belongs to the best of the industry, outperforming 89.53% of the companies in the same industry.
  • In the last couple of years the Profit Margin of GSK has declined.
  • GSK's Operating Margin of 27.47% is amongst the best of the industry. GSK outperforms 93.19% of its industry peers.
  • GSK's Operating Margin has improved in the last couple of years.
  • The Gross Margin of GSK (72.67%) is better than 80.10% of its industry peers.
  • In the last couple of years the Gross Margin of GSK has remained more or less at the same level.
Industry RankSector Rank
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
GSK Yearly Profit, Operating, Gross MarginsGSK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GSK is creating value.
  • GSK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GSK Yearly Shares OutstandingGSK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
GSK Yearly Total Debt VS Total AssetsGSK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

  • An Altman-Z score of 2.39 indicates that GSK is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • GSK has a Altman-Z score of 2.39. This is in the better half of the industry: GSK outperforms 63.35% of its industry peers.
  • GSK has a debt to FCF ratio of 3.73. This is a good value and a sign of high solvency as GSK would need 3.73 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.73, GSK belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
  • GSK has a Debt/Equity ratio of 0.90. This is a neutral value indicating GSK is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.90, GSK is not doing good in the industry: 71.73% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Altman-Z 2.39
ROIC/WACC2.09
WACC9.16%
GSK Yearly LT Debt VS Equity VS FCFGSK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 0.82 indicates that GSK may have some problems paying its short term obligations.
  • GSK has a Current ratio of 0.82. This is amonst the worse of the industry: GSK underperforms 87.96% of its industry peers.
  • GSK has a Quick Ratio of 0.82. This is a bad value and indicates that GSK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • GSK's Quick ratio of 0.54 is on the low side compared to the rest of the industry. GSK is outperformed by 88.48% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.54
GSK Yearly Current Assets VS Current LiabilitesGSK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • GSK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.95%, which is quite impressive.
  • GSK shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.30% yearly.
  • GSK shows a small growth in Revenue. In the last year, the Revenue has grown by 4.11%.
  • The Revenue has been growing slightly by 6.05% on average over the past years.
EPS 1Y (TTM)22.95%
EPS 3Y9.83%
EPS 5Y6.3%
EPS Q2Q%113.73%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%2.99%

3.2 Future

  • Based on estimates for the next years, GSK will show a small growth in Earnings Per Share. The EPS will grow by 2.61% on average per year.
  • The Revenue is expected to grow by 2.98% on average over the next years.
EPS Next Y-4.56%
EPS Next 2Y1.8%
EPS Next 3Y5.19%
EPS Next 5Y2.61%
Revenue Next Year5.1%
Revenue Next 2Y4.85%
Revenue Next 3Y4.35%
Revenue Next 5Y2.98%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GSK Yearly Revenue VS EstimatesGSK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
GSK Yearly EPS VS EstimatesGSK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 11.17, which indicates a very decent valuation of GSK.
  • Based on the Price/Earnings ratio, GSK is valued cheaper than 90.05% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.92, GSK is valued rather cheaply.
  • The Price/Forward Earnings ratio is 11.71, which indicates a very decent valuation of GSK.
  • 86.91% of the companies in the same industry are more expensive than GSK, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.78, GSK is valued rather cheaply.
Industry RankSector Rank
PE 11.17
Fwd PE 11.71
GSK Price Earnings VS Forward Price EarningsGSK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • GSK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GSK is cheaper than 91.10% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of GSK indicates a rather cheap valuation: GSK is cheaper than 86.91% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 18.82
EV/EBITDA 8.02
GSK Per share dataGSK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The excellent profitability rating of GSK may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.77
EPS Next 2Y1.8%
EPS Next 3Y5.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 3.21%, GSK has a reasonable but not impressive dividend return.
  • GSK's Dividend Yield is rather good when compared to the industry average which is at 0.61. GSK pays more dividend than 94.76% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.83, GSK pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.21%

5.2 History

  • The dividend of GSK decreases each year by -9.84%.
  • GSK has been paying a dividend for at least 10 years, so it has a reliable track record.
  • The dividend of GSK decreased recently.
Dividend Growth(5Y)-9.84%
Div Incr Years1
Div Non Decr Years1
GSK Yearly Dividends per shareGSK Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2

5.3 Sustainability

  • 44.86% of the earnings are spent on dividend by GSK. This is a bit on the high side, but may be sustainable.
DP44.86%
EPS Next 2Y1.8%
EPS Next 3Y5.19%
GSK Yearly Income VS Free CF VS DividendGSK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B
GSK Dividend Payout.GSK Dividend Payout, showing the Payout Ratio.GSK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

GSK PLC-SPON ADR

NYSE:GSK (2/6/2026, 8:04:00 PM)

After market: 60.03 -0.2 (-0.33%)

60.23

+1.06 (+1.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)04-28
Inst Owners43.55%
Inst Owner Change204.24%
Ins Owners0.1%
Ins Owner ChangeN/A
Market Cap121.49B
Revenue(TTM)32.67B
Net Income(TTM)5.72B
Analysts70.97
Price Target51.62 (-14.3%)
Short Float %0.89%
Short Ratio4.14
Dividend
Industry RankSector Rank
Dividend Yield 3.21%
Yearly Dividend1.64
Dividend Growth(5Y)-9.84%
DP44.86%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)62.08%
Min EPS beat(2)12.8%
Max EPS beat(2)111.35%
EPS beat(4)4
Avg EPS beat(4)35.42%
Min EPS beat(4)7.67%
Max EPS beat(4)111.35%
EPS beat(8)8
Avg EPS beat(8)24.63%
EPS beat(12)11
Avg EPS beat(12)18.06%
EPS beat(16)15
Avg EPS beat(16)16.62%
Revenue beat(2)0
Avg Revenue beat(2)-2.24%
Min Revenue beat(2)-4.2%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-4.2%
Max Revenue beat(4)-0.04%
Revenue beat(8)3
Avg Revenue beat(8)-0.53%
Revenue beat(12)7
Avg Revenue beat(12)1%
Revenue beat(16)9
Avg Revenue beat(16)-0.36%
PT rev (1m)1.93%
PT rev (3m)12.32%
EPS NQ rev (1m)-2.77%
EPS NQ rev (3m)-6.08%
EPS NY rev (1m)0.81%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)2.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.14%
Valuation
Industry RankSector Rank
PE 11.17
Fwd PE 11.71
P/S 2.74
P/FCF 18.82
P/OCF 11.56
P/B 5.46
P/tB N/A
EV/EBITDA 8.02
EPS(TTM)5.39
EY8.95%
EPS(NY)5.14
Fwd EY8.54%
FCF(TTM)3.2
FCFY5.31%
OCF(TTM)5.21
OCFY8.65%
SpS21.99
BVpS11.02
TBVpS-4.97
PEG (NY)N/A
PEG (5Y)1.77
Graham Number36.56
Profitability
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROCE 22.59%
ROIC 19.19%
ROICexc 20.98%
ROICexgc 60.71%
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
FCFM 14.56%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
F-Score9
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Debt/EBITDA 1.15
Cap/Depr 79.01%
Cap/Sales 9.14%
Interest Coverage 13.22
Cash Conversion 60.7%
Profit Quality 83.21%
Current Ratio 0.82
Quick Ratio 0.54
Altman-Z 2.39
F-Score9
WACC9.16%
ROIC/WACC2.09
Cap/Depr(3y)99.36%
Cap/Depr(5y)105.31%
Cap/Sales(3y)8.79%
Cap/Sales(5y)9.19%
Profit Quality(3y)103.9%
Profit Quality(5y)92.12%
High Growth Momentum
Growth
EPS 1Y (TTM)22.95%
EPS 3Y9.83%
EPS 5Y6.3%
EPS Q2Q%113.73%
EPS Next Y-4.56%
EPS Next 2Y1.8%
EPS Next 3Y5.19%
EPS Next 5Y2.61%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%2.99%
Revenue Next Year5.1%
Revenue Next 2Y4.85%
Revenue Next 3Y4.35%
Revenue Next 5Y2.98%
EBIT growth 1Y15.03%
EBIT growth 3Y2.25%
EBIT growth 5Y8.41%
EBIT Next Year30.24%
EBIT Next 3Y13.85%
EBIT Next 5Y8.05%
FCF growth 1Y33.15%
FCF growth 3Y-2.59%
FCF growth 5Y-5.17%
OCF growth 1Y18.11%
OCF growth 3Y1.5%
OCF growth 5Y-1.72%

GSK PLC-SPON ADR / GSK FAQ

Can you provide the ChartMill fundamental rating for GSK PLC-SPON ADR?

ChartMill assigns a fundamental rating of 6 / 10 to GSK.


What is the valuation status of GSK PLC-SPON ADR (GSK) stock?

ChartMill assigns a valuation rating of 8 / 10 to GSK PLC-SPON ADR (GSK). This can be considered as Undervalued.


How profitable is GSK PLC-SPON ADR (GSK) stock?

GSK PLC-SPON ADR (GSK) has a profitability rating of 8 / 10.


What is the financial health of GSK PLC-SPON ADR (GSK) stock?

The financial health rating of GSK PLC-SPON ADR (GSK) is 4 / 10.


What is the earnings growth outlook for GSK PLC-SPON ADR?

The Earnings per Share (EPS) of GSK PLC-SPON ADR (GSK) is expected to decline by -4.56% in the next year.